Why Shares of Novo Nordisk Stock Sank (Again) This Week
Key Points
Novo Nordisk lost another head-to-head trial against Eli Lilly.
The company is cutting prices on weight-loss drugs in 2026.
The stock looks cheap, but earnings could fall from here.
- 10 stocks we like better than Eli Lilly ›
Shares of Novo Nordisk (NYSE: NVO) sank 20% this week, according to data from S&P Global Market Intelligence. The drugmaker behind the weight-loss drug craze is in the midst of a terrible drawdown -- 75% as of this writing -- due to a bad trial for its new weight-loss drug in a head-to-head battle with Eli Lilly. Plus, the company announced additional price cuts for its weight-loss drug Wegovy in 2027, due to pressure from the U.S. government.
Here's why Novo Nordisk stock fell again this week, and whether it is a buy right now.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Falling behind the competition and more cost cuts
Novo Nordisk has a new weight-loss drug called CagriSema that it hopes will be more effective than its initial blockbuster, Wegovy, in helping patients lose weight. To prove its might, Novo Nordisk conducted a trial to compare the performance of CagriSema vs. Eli Lilly's Zepbound. However, the trial results were not in Novo Nordisk's favor, with patients who used Zepbound losing slightly more weight than those who used CagriSema.
This difference in efficacy is why Eli Lilly's stock has soared while Novo Nordisk's has faltered. In the last three years, Eli Lilly's revenue has grown by 135% compared to 77% for Novo Nordisk, with Novo Nordisk's revenue growth beginning to stagnate at the same time that Lilly's is accelerating. The two-horse race in weight-loss drugs is currently dominated by Eli Lilly, leaving Novo Nordisk shareholders in a painful position.
On top of the intense competition, Novo Nordisk is getting battered by a recent announcement that it will again cut prices on its weight-loss drug portfolio in the United States in 2027. The cuts could reach 50% to make U.S. customers and the government happy, and the potential loss of revenue could be staggering.
Image source: Getty Images.
Is Novo Nordisk stock a buy?
Novo Nordisk stock now trades at a price-to-earnings ratio (P/E) approaching 10, which is much lower than Eli Lilly's. However, investors likely see the writing on the wall regarding market share losses and price cuts for the business. Unless you are a believer that Novo Nordisk will leapfrog Eli Lilly again, the stock is likely one that you should avoid buying for your portfolio.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $445,995!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,198,823!*
Now, it’s worth noting Stock Advisor’s total average return is 927% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 26, 2026.
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
